Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.65 |
| ▸ | TP53 | P04637 | 3/20 | 0.59 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18890871 | 0.81 | MAPT (0.73) | MAPTTP53SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL18890874 | 0.81 | MAPT (0.84) | MAPTTP53STING1SMN1; SMN2LMNA | |
| SCHEMBL21972639 | 0.80 | STING1 (0.81) | MAPTTP53STING1SMN1; SMN2LMNA | |
| SCHEMBL21972318 | 0.80 | STING1 (0.81) | MAPTTP53STING1SMN1; SMN2LMNA | |
| SCHEMBL18864289 | 0.80 | MAPT (0.73) | MAPTTP53STING1SMN1; SMN2LMNA | |
| SCHEMBL18890872 | 0.79 | STING1 (0.89) | MAPTTP53STING1SMN1; SMN2LMNA | |
| SCHEMBL21972652 | 0.79 | MAPT (1.00) | MAPTTP53STING1SMN1; SMN2LMNA | |
| SCHEMBL21972669 | 0.78 | TP53 (0.82) | MAPTTP53STING1SMN1; SMN2LMNA | |
| SCHEMBL25922279 | 0.77 | CTDSP1 (0.58) | MAPTTP53SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL21972956 | 0.77 | TP53 (0.78) | MAPTTP53SMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170146519-A1 | STING AGONISTS AND METHODS OF SELECTING STING AGONISTS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170146519-A1 | STING AGONISTS AND METHODS OF SELECTING STING AGONISTS | STING1, IRF3, MAVS | MAPT 4720/4885TP53 286/4885STING1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.